IXHL: Incannex Healthcare Inc. Stock

by  •  • Comments Off on IXHL: Incannex Healthcare Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 28.75
Enterprise Value ($M) 30.42
Book Value ($M) 0.96
Book Value / Share 0.05
Price / Book 29.80
NCAV ($M) 0.36
NCAV / Share 0.02
Price / NCAV 79.21

Profitability (mra)
Return on Invested Capital (ROIC) -4.70
Return on Assets (ROA) -1.06
Return on Equity (ROE) -1.26

Liquidity (mrq)
Quick Ratio 1.80
Current Ratio 1.80

Balance Sheet (mrq) ($M)
Current Assets 10.50
Assets 11.11
Liabilities 10.14
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.01
Operating Income -18.61
Net Income -18.46

Cash Flow Statement (mra) ($M)
Cash From Operations -15.85
Cash from Investing -0.28
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPOR
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-09-30 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT T

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 2,324 7,015 33.13
2025-02-20 1,590 18,739 8.48
2025-02-19 3,908 66,797 5.85
2025-02-18 8,132 33,726 24.11

(click for more detail)

Similar Companies
IRON – Disc Medicine, Inc. ITOS – iTeos Therapeutics, Inc.
IVVD – Invivyd, Inc. JANX – Janux Therapeutics, Inc.
KALV – KalVista Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io